Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering
Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally
SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions.
Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace.
Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive a dashboard providing de-identified, amalgamated data on the well-being of their workforce leveraging both the subjective and objective metrics. Employees then have the option to connect their wearable devices, such as Apple Watch, Garmin, and Fitbit, collect heart rate and sleep data.
The first-phase contract extends Medibio's engagement with Jacob's beyond Asia Pacific, to now encompass over 8,000 employees across Asia Pacific, India, the Middle East and Europe. The Check-In will be rolled out to Jacobs' European leadership team alongside the Asia Pacific and Middle Eastern workforces and is projected to generate first-stage revenue of approximately $50,000 for the initial four-week program. Services, including consultancy and delivery of ongoing mental health interventions and programs, will be billed as provided.
The correlation of ANS biometrics and mental health has been the focus of the company for over 20 years. Especially while sleeping, our bodies reflect our mental state through the performance of the autonomic nervous system. Medibio's technology platform detects dysfunction within the areas of the body regulated by the ANS, and through proprietary data processing and algorithms, the technology correlates these anomalies to different mental health conditions. It is a profound discovery that for the first time provides a tangible, objective understanding of mental health.
"We are thrilled to extend our pivotal agreement with Jacobs Engineering, a long-term supporter of Medibio and a leading corporation in driving the way mental health care is delivered to their employee base," said CEO and Managing Director Jack Cosentino. "By leveraging our proprietary technology, in conjunction with Jacobs' strong corporate advocacy, we look forward to establishing a long-term relationship to enable real change in the area of corporate mental health."
Jacobs Engineering Group is one of the world's largest engineering and environmental consultancy groups. With a reputation for innovation, performance, and a human centric approach to employment and consultancy they have sought out programs that align with their values and integrate with their culture. Jacobs currently employs over 70,000 employees in over 250 offices worldwide.
Patrick Hill, Sr. Vice President and General Manager Buildings, Infrastructure and Advanced Facilities at Jacobs said: "Our partnership with Medibio appears to have been hugely beneficial to date. Their analytical and evidence-based approach is a significant step forward for an organization like Jacobs that is looking to move from awareness to action, and from reaction to prevention. As a company that aims to puts its people first, we are delighted to be extending the Check-in to other parts of our global business."
This contract signed by Jacobs Engineering continues Medibio's rapidly expanding portfolio of global companies participating in the Mental Health Check-in including:
- Jacobs Engineering (U.S.)
- St. John of God Health Care (Australia's third-largest healthcare provider)
- Australian Football League (AFL)
- Rio Tinto
- Aurecon Jacobs Joint Venture for West Gate Tunnel Project
The Mental Health Check-in Campaign is the entry-level offering to Medibio's Corporate Health products and is rapidly positioning Medibio as the preeminent mental health technology and services provider offering comprehensive mental health solutions for businesses.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Jacobs leads the global professional services sector delivering solutions for a more connected, sustainable world. With $15 billion in fiscal 2017 revenue when combined with full-year CH2M revenues and a talent force of more than 77,000, Jacobs provides a full spectrum of services including scientific, technical, professional and construction- and program-management for business, industrial, commercial, government and infrastructure sectors. For more information, visit www.jacobs.com, and connect with Jacobs on LinkedIn, Twitter, Facebook and Instagram.
|Further Information:||Website: www.medibio.com.au|
T: 952-222-0551 ext. 208
T: +61 434 405 400
A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/dca9e5bd-b9a4-4500-9840-9530068038c8
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million18.9.2019 13:00:00 CEST | Press release
CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 18 SEPTEMBER 2019 AT 2:00 PM (EEST) Cargotec files listing application in respect of its bonds in the aggregate amount of EUR 250 million NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Cargotec Plc decided on 13 September 2019 to issue two unsecured bonds in the total aggregate nominal amount of EUR 250 million. The first EUR 100 million bond matures on 23 January 2025 and carries a fixed annual interest of 1.250 per cent (ISIN: FI4000399688). The other, a EUR 150 million bond matures on 23 September 2026 and carries a fixed annual interest of 1.625 per cent (ISIN: FI4000399696). Cargotec Plc has today filed an application with Nasdaq Helsinki Ltd for the admission to trading of the bonds on the official list of Nasdaq Helsinki Ltd. Such application is subject to the F
New liquidity providing agreement for Aspo Plc’s share18.9.2019 12:00:00 CEST | Press release
ASPO Plc Stock exchange release September 18, 2019 at 13:00 New liquidity providing agreement for Aspo Plc’s share Aspo Plc and Lago Kapital Ltd have signed a market making agreement in compliance with the Liquidity Providing (LP) requirements issued by Nasdaq Helsinki Ltd. Concurrently, Aspo has terminated its current liquidity providing agreement with Nordea Bank. The current agreement will be in force until Friday October 18, 2019. The new liquidity providing agreement will commence on Monday 21 October, 2019. According to the agreement, Lago Kapital Ltd will provide Aspo’s share with bids and offers so that the maximum spread is 3 per cent, calculated from the bid quotation. Both bid and offer side shall include a number of shares corresponding to the value of at least 3,000 euros. The agreement is in force for a fixed period of 3 months and thereafter until terminated with one month’s term of notice. The market making agreement aims at increasing the share's liquidity and decreasi
Suominen’s financial reporting in 202018.9.2019 12:00:00 CEST | Press release
Suominen Corporation's stock exchange release on September 18, 2019 at 1:00 p.m. EEST Suominen will publish its Financial Statements Release, Half Year Financial Report and two Interim Reports in 2020 as follows: January 29, 2020 - Financial Statements Release for 2019 April 23, 2020 - Interim Report for January-March 2020 August 12, 2020 - Half Year Financial Report for January-June 2020 October 22, 2020 - Interim Report for January-September 2020 The Annual Report for 2019 will be published during the week starting on February 24, 2020 (week 9) at the latest. Suominen's Annual General Meeting is planned to be held on Thursday, March 19, 2020. Suominen's Board of Directors will summon the meeting at a later date. For more information: Emilia Peltola, VP, Communications and IR, tel. +358 10 214 3082 Suominen manufactures nonwovens as roll goods for wipes as well as for medical and hygiene products. The end products made of Suominen’s nonwovens – wet wipes, feminine care products and sw
Nomination Committee for SEB appointed18.9.2019 10:00:00 CEST | Press release
Press release Stockholm 18 September 2019 Nomination Committee for SEB appointed SEB’s Annual General Meeting will be held on Monday, 23 March 2020. The Nomination Committee members are: Petra Hedengran, Investor, Chairman Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, Chairman of the Board, SEB The shareholders having appointed members of the Nomination Committee together represent approximately 36,1 per cent of the voting rights for all shares in the Bank. The SEB Board has appointed Sven Nyman additional member of the Committee. The Nomination Committee will prepare a proposal for Directors etc. to be presented to the Annual General Meeting 2020 for decision. The matters to be dealt with by the Nomination Committee are described on www.sebgroup.com under the heading ‘Annual General Meeting’. A shareholder who would like to submit a proposal to the Nomination Committee can do so by e-mail to firstname.lastname@example.org or by ordinary
Valberedning för SEB utsedd18.9.2019 10:00:00 CEST | Pressemelding
Pressmeddelande Stockholm 18 september 2019 Valberedning för SEB utsedd Årsstämma för Skandinaviska Enskilda Banken kommer att hållas måndagen den 23 mars 2020. Valberedningen består av: Petra Hedengran, Investor, ordförande Magnus Billing, Alecta Lars Heikensten, Trygg-Stiftelsen Johan Sidenmark, AMF Marcus Wallenberg, styrelsens ordförande, SEB De aktieägare som utsett ledamöter till valberedningen, representerar tillsammans cirka 36,1 procent av röstetalet för samtliga aktier i banken. SEB:s styrelse har utsett Sven Nyman att vara adjungerad ledamot av valberedningen. Valberedningen har till uppgift att arbeta fram ett förslag till styrelse m.m. att läggas fram för beslut på årsstämman 2020. De frågor valberedningen ska behandla finns beskrivna på www.sebgroup.com/sv under rubriken ”Årsstämma”. Aktieägare som önskar lämna förslag till valberedningen kan göra det med e-post till email@example.com eller med brev till Skandinaviska Enskilda Banken AB, Valberedningen, Att: Ulf Thornan
MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets18.9.2019 09:00:00 CEST | Press release
DUBLIN, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*1, also surpasses the recommended target.3 The SmartGuard™ Auto Mode feature in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day. This system is the only commercially available technology in the world to provide protection from highs and lows, and proactively drive increased Time in Range by consistently guiding to the target of 120 mg/dL (6.7mmol/L) throughout the day.4,5 “The Time in Range clinical guidelines recommend that the target of effective diabetes management